Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Desogestrel (DSG) and Corifollitropin(FSH-CTP) Alfa for Ovarian Stimulation in Donors
NCT02757287 · Fundacion Dexeus · PHASE4 · withdrawn · last registry update 2018-09-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of financial support” | – | Registry record, Fundacion Dexeus |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FSHR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-08-19Results posted on the registry: Instituto Bernabeu, Gonadotrophins + GnRH antagonist (NCT02821819)
- 2019-08-19Also stopped (terminated): Instituto Bernabeu, Gonadotrophins + GnRH antagonist (NCT02821819)
- 2019-08-05Results posted on the registry: IVFarma LLC, Follitropin alfa (Primapur) + Follitropin alfa (Gonal-F) (NCT03857230)
- 2019-06-06Results posted on the registry: IVFarma LLC, Follitropin alfa (Gonal-f) + Follitropin alfa (Primapur) (NCT03088137)
- 2019-03-08Also stopped (terminated): Mount Sinai Hospital, Canada, Nimodipine + Placebo (NCT01551368)
- 2019-01-29Also stopped (terminated): UMC Utrecht, Mild stimulation (NCT00823472)
- 2019-01-18Phase 3 first posted: Ferring Pharmaceuticals, FE 999049 + GnRH agonist (GONAPEPTYL) + FE 999049 + GnRH antagonist (CETROTIDE) (NCT03809429)
- 2018-11-26Results posted on the registry: University Medical Centre Ljubljana, Elonva (NCT02606500)
- 2018-11-14Phase 3 first posted: Ferring Pharmaceuticals, Follitropin delta (NCT03740737)
- 2018-11-13Phase 3 first posted: Ferring Pharmaceuticals, Follitropin delta + Placebo (NCT03738618)
- 2018-09-25Results posted on the registry: Ferring Pharmaceuticals, Follitropin Delta (FE 999049) + Follitropin Alfa (GONAL-F) (NCT01956110)
- 2018-09-21Results posted on the registry: Ferring Pharmaceuticals, Follitropin Delta (FE 999049) + Follitropin Alfa (GONAL-F) (NCT01956123)
- 2018-09-14Also stopped (terminated): St. Olavs Hospital, fostimon + puregon (NCT01882166)
- 2018-08-07Also stopped (terminated): University Reproductive Associates, Luveris fixed dose + Luveris increasing dose (NCT00889512)
- 2018-08-03Results posted on the registry: Ferring Pharmaceuticals, FE 999049 + Gonal - F (NCT01426386)
- 2018-07-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, r-FSH + r-hLH (NCT01112358)
- 2018-05-29Results posted on the registry: Fertility Biotech AG, Afolia + US Gonal-f® (NCT02459418)
- 2018-04-24Phase 3 first posted: Hangzhou YuYuan Bioscience Technology Co., Ltd., Follitrope PFS + Gonal-f pen (NCT03506243)
- 2018-04-06Results posted on the registry: Merck KGaA, Darmstadt, Germany, GONAL-f® (NCT01183143)
- 2018-03-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, Gonal-f + Recombinant human chorionic gonadotrophin (r-hCG) (NCT00249834)
- 2018-03-27Results posted on the registry: Merck KGaA, Darmstadt, Germany, Recombinant human follicle stimulating hormone (r-hFSH) + Recombinant human luteinizing hormone (r-hLH) (NCT01110707)
- 2018-03-02Results posted on the registry: Ferring Pharmaceuticals, menotropin + recombinant FSH (NCT02554279)
- 2018-03-02Also stopped (terminated): Instituto de Investigacion Sanitaria La Fe, Bravelle (NCT02605070)
- 2018-02-23Results posted on the registry: Wake Forest University Health Sciences, clomiphene plus gonadotropins + Leuprolide flare (NCT01921166)
- 2017-10-18Results posted on the registry: Fertility Biotech AG, AFOLIA + Gonal-f® RFF (NCT01687712)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision